These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1179 related articles for article (PubMed ID: 29178633)

  • 1. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
    Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
    J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century.
    ─îivljak R; Giannella M; Di Bella S; Petrosillo N
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):249-64. PubMed ID: 24392752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
    Tiwari V; Meena K; Tiwari M
    Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
    Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
    Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
    Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
    Seifert H; Blondeau J; Dowzicky MJ
    Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.
    Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN
    Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017.
    Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O
    S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Amino-4-aminoximidofurazan derivatives: small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa.
    Das MC; Paul S; Gupta P; Tribedi P; Sarkar S; Manna D; Bhattacharjee S
    J Appl Microbiol; 2016 Apr; 120(4):842-59. PubMed ID: 26785169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
    Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
    Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa PA14 Enhances the Efficacy of Norfloxacin against Staphylococcus aureus Newman Biofilms.
    Orazi G; Jean-Pierre F; O'Toole GA
    J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32661077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biofilm contamination of high-touched surfaces in intensive care units: epidemiology and potential impacts.
    Costa DM; Johani K; Melo DS; Lopes LKO; Lopes Lima LKO; Tipple AFV; Hu H; Vickery K
    Lett Appl Microbiol; 2019 Apr; 68(4):269-276. PubMed ID: 30758060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
    Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
    Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
    Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
    Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipathogenic Efficacy of Biogenic Silver Nanoparticles and Antibiofilm Activities Against Multi-drug-Resistant ESKAPE Pathogens.
    Khan MH; Unnikrishnan S; Ramalingam K
    Appl Biochem Biotechnol; 2024 Apr; 196(4):2031-2052. PubMed ID: 37462813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives for the treatment of infections caused by ESKAPE pathogens.
    da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; H├Ârner R
    J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
    Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
    Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.